SNM Annual Meeting Abstracts
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     



J Nucl Med. 2008; 49 (Supplement 1):20P
This Article
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Google Scholar
Right arrow Articles by Stillebroer, A.
Right arrow Articles by Oyen, W.
PubMed
Right arrow Articles by Stillebroer, A.
Right arrow Articles by Oyen, W.

Oncology: Special Sessions

Nuclear Oncology Council Young Investigator Award Symposium

Radioimmunotherapy with Lutetium-177 labeled monoclonal antibody cG250 in patients with advanced renal cell carcinoma

Alexander Stillebroer1, Otto Boerman1, Egbert Oosterwijk2, Peter Mulders2 and Wim Oyen1

1 Nuclear Medicine; 2 Urology, Radboud University Nijmegen Medical Center, Nijmegen, Netherlands

77

Objectives: MAb cG250 recognizes carbonic anhydrase IX (CAIX), an antigen that is overexpressed in clear cell Renal Cell Carcinoma (ccRCC). A phase I/II RIT study with 131I-cG250 in metastatic RCC patients showed only minor clinical responses. 111In-cG250 revealed superior tumor uptake as compared to 131I-cG250 in an intra-patient comparative study. RIT studies in mice with RCC xenografts demonstrated superior therapeutic efficacy of 177Lu-cG250 as compared to 131I-cG250. Aim: In this study in RCC patients we aim to determine the MTD and therapeutic efficacy of multiple infusions of 177Lu-cG250.

Methods: Adequate cG250 accumulation in metastatic ccRCC lesions was verified by imaging of a diagnostic dose of 111In-cG250. Eligible patients received high dose 177Lu-cG250. The initial dose level was 30 mCi/m2, followed by dose increments of 10 mCi/m2 until the maximum tolerated dose. In the absence of progressive disease after 14 weeks, patients were eligible for re-treatment.

Results: At the highest dose level (60 mCi/m2) myelotoxicity did not exceed grade 3 (CTC-criteria). 177Lu-cG250 showed good targeting of the tumor lesions in all 13 study patients. The 111In-cG250 images could be used to predict 177Lu-cG250 dosimetry. Patients received 2nd (9/13) and 3rd (3/13) treatment cycles. Most patients (10/13) demonstrated stable disease after 14 weeks and one patient showed a partial response, which lasted for 10 months.

Conclusions: 177Lu-cG250 showed excellent tumor targeting of RCC lesions. 60 mCi/m2 could be safely administered to patients, and dose escalation is ongoing. Preliminary clinical observations indicate that 177Lu-cG250 treatment could stabilize previously progressive metastatic RCC.





This Article
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Google Scholar
Right arrow Articles by Stillebroer, A.
Right arrow Articles by Oyen, W.
PubMed
Right arrow Articles by Stillebroer, A.
Right arrow Articles by Oyen, W.